Budesonide/formoterol maintenance and reliever therapy via <scp>T</scp>urbuhaler versus fixed‐dose budesonide/formoterol plus terbutaline in patients with asthma: Phase <scp>III</scp> study results

Atienza, Tito; Aquino, Teresita O.; Fernández, Marcelo; Boonsawat, Watchara; Kawai, Mitsuru; Kudo, Takahide; Ekelund, Jan; Ivanov, Stefan; Carlsson, Linda

doi:10.1111/resp.12009

Cited by 29 publications

(38 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The following studies contained inclusion criteria that required a history of an exacerbation in the 12 months prior to randomisation [18, 19, 21-23, 25, 27-29]. The risk of severe exacerbation (AIR versus traditional algorithm) was reported as relative rate [6, 15, 16, 19, 21, 23-25, 27, 29], relative risk [7,17,28] and hazard ratio [18,22], respectively. Studies prescribed reliever therapy as follows; budesonide/formoterol (B/F) 200/6 μg, one actuation as required for relief of symptoms [6,7,15,16,19,21,22,24,25,[27][28][29]; B/F 100/6 μg, one actuation as required for relief of symptoms [17,18]; ultrafine beclometasone dipropionate/formoterol 100/6 μg (BDP/F), one actuation as required for relief of symptoms [23].…”

Section: Stepmentioning

confidence: 99%

“…actuation as-needed [20][21][22], budesonide/formoterol 100/6 µg Turbuhaler two actuations once daily as maintenance together with one actuation as needed [17], and budesonide/formoterol 100/6 µg Turbuhaler one actuation twice daily as maintenance together with one actuation as-needed [18]. It may be preferable to use the budesonide/formoterol 200/6 µg Turbuhaler, as this reduces treatment complexity and enables standardisation of the 200/6 µg dose per actuation across the different steps of this proposed algorithm.…”

Section: Stepmentioning

confidence: 99%

See 1 more Smart Citation

ICS-formoterol reliever therapy stepwise treatment algorithm for adult asthma

et al. 2020

View full text Add to dashboard Cite

show abstract

Section: Stepmentioning

confidence: 99%

Section: Stepmentioning

confidence: 99%

ICS-formoterol reliever therapy stepwise treatment algorithm for adult asthma

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Seven studies that met the criteria were identified in the AstraZeneca clinical trial database: SD-039-0667 (STEAM) [10], SD-039-0668 (STEP) [11], SD-039-0673 (STAY) [12], SD-039-0734 (SMILE) [13], SD-039-0735 (COMPASS) [14], NCT00242775 (AHEAD) [15] and NCT00839800 (SAKURA) [16]. Of these, six were included in the analysis: NCT00839800 was excluded since it randomised only 21 adolescents, all of whom were aged ⩾16 years.…”

Section: Methodsmentioning

confidence: 99%

Budesonide/formoterol maintenance and reliever therapy in adolescent patients with asthma

Jorup

Lythgoe²,

Bisgaard

2018

Eur Respir J

View full text Add to dashboard Cite

Asthma control is often suboptimal in adolescents, but few studies have evaluated asthma treatments in this population.This analysis assessed the efficacy and safety of budesonide/formoterol (BUD/FORM) maintenance and reliever therapy (MART) for treatment of persistent asthma in adolescent (age 12-17 years) subgroups within six randomised, double-blind trials. The primary end-point was time to first severe exacerbation. Secondary end-points included number of severe exacerbations, asthma-related symptoms, night-time awakenings, morning peak expiratory flow, forced expiratory volume in 1 s, as-needed medication use and five-item asthma control questionnaire scores.In adolescents (n=1847), BUD/FORM MART was similar to or more effective than comparators across each of the studies in reducing the risk of a first severe exacerbation (hazard ratios (HR) BUD/FORM MART comparators 0.15-1.01; pooled HR 0.49, 95% CI 0.34-0.70), with comparable outcomes to the adult subgroups (n=12 197). Similar treatment benefits for BUD/FORM MART were observed for secondary end-points. As-needed medication use was lower with BUD/FORM MART than comparators, and BUD/FORM as-needed use was lower in adolescents than adults. Treatment was well tolerated.This analysis supports the use of BUD/FORM MART in adolescents with persistent asthma, its efficacy and safety being consistent with that reported for adults.

show abstract

“…ICS and ICS/ LABA are used as a first choice for asthma treatment around the world. The effectiveness of ICS and ICS/LABA for asthma treatment is supported in plural large clinical trials [21][22][23][24][25][26][27][28][29].…”

Section: Discussionmentioning

confidence: 99%

Diaphragm Muscle Contraction Decrease in a Mouse Model of Ovalbumin-Induced Allergic Airway Inflammation

Yamaguchi¹,

Shindoh²,

Miura³

2017

J Allergy Ther

View full text Add to dashboard Cite

Objective: We investigated diaphragm contractile and inflammatory properties of mice with OVA sensitization and challenge.Methods: BALB/c mice were sensitized to OVA by intraperitoneal (i.p.) injection at 0 and 7 days, and challenged with aerosolized OVA on 21, 22, and 23 days (O/O group). Budesonide/Formoterol combination was inhaled on days 21, 22, and 23 before OVA challenge on those same days (O/OC group). Control mice were sensitized and challenged with an aerosolized saline (O-group). The diaphragm contractile and inflammatory properties were measured on day 24. NOS activity in the diaphragm muscle was evaluated by NADPH diaphorase staining. IL-4 and IL-13 levels of BALF, as well as lung tissue and diaphragm muscle homogenates were measured by ELISA. Conclusions:OVA sensitization and challenge decreased diaphragm muscle contraction, increased NOS activity, IL-4 levels of diaphragm in a mouse model. Budesonide/Formoterol combination could protect diaphragm muscle weakness and inflammation. According to the traditional concept of the contemporary Immunology, neither autoimmune diseases nor allergic diseases can be cured completely. Nevertheless, a fortunate coincidence led me to discovery of a novel concept that eliminations of the causes of these diseases are possible. In other words, combinations of pathogenic antibodies with responsible cells, namely, cytolytic T lymphocytes in cases of autoimmune diseases and mast cells in cases of allergic diseases, can be decomposed by replacing the pathogenic antibodies with non-specific antibodies. In more detail, intradermal injections with a non-specific antigen preparation induce production of non-specific antibodies in the body of the patient. Repetitions of the injections bring about an accumulation of them. Accumulated non-specific antibodies will occupy most of the receptors on the surface of responsible cells. When the accumulation reaches the sufficient level, virtually no pathogenic antibodies would remain on the receptors. That is, no causes of the diseases remain. Naturally, where there is no cause, there is no disease. Details are demonstrated elsewhere.

show abstract

Budesonide/formoterol maintenance and reliever therapy via Turbuhaler versus fixed‐dose budesonide/formoterol plus terbutaline in patients with asthma: Phase III study results

Cited by 29 publications

References 19 publications

ICS-formoterol reliever therapy stepwise treatment algorithm for adult asthma

ICS-formoterol reliever therapy stepwise treatment algorithm for adult asthma

Budesonide/formoterol maintenance and reliever therapy in adolescent patients with asthma

Diaphragm Muscle Contraction Decrease in a Mouse Model of Ovalbumin-Induced Allergic Airway Inflammation

Contact Info

Product

Resources

About